Immucothel (Immunocyanine, Standardised)

Immunocyanine is believed to interact with surface receptors on lymphocytes, triggering intracellular signaling that influences cytokine production and cell proliferation. This modulation can shift the balance between immune activation and tolerance, potentially altering the overall immune response. The precise molecular mechanisms are still being defined in pre‑clinical and early clinical studies.

The dosing regimen for Immucothel is determined by the prescribing clinician based on the specific study protocol or therapeutic context. No fixed dose is publicly established; healthcare professionals calculate the appropriate amount according to patient characteristics, indication under investigation, and regulatory guidance.

Safety data for Immucothel during pregnancy and lactation are limited. Because the potential effects on the fetus or nursing infant are not well characterized, the product should only be used if the anticipated benefit outweighs any possible risk, and after a thorough risk‑benefit assessment by the treating physician.

To request Immucothel, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain logistics if needed), and required import documentation.

Immucothel’s active component, Immunocyanine, differs from conventional small‑molecule immunomodulators and monoclonal antibodies in its proposed mechanism of receptor‑mediated lymphocyte modulation. While comparative clinical data are limited, its profile may offer a distinct safety and pharmacodynamic profile, but head‑to‑head efficacy data are not yet available.

Immucothel must be stored at 2‑8 °C in a refrigerator, protected from light, and should never be frozen or shaken. The product should be kept in its original packaging until use to maintain stability and potency.

Immucothel is supplied as an injectable preparation for intradermal or subcutaneous administration. The injection should be performed by a qualified healthcare professional using aseptic technique, following the dosing instructions provided in the clinical protocol or prescribing information.

The most serious adverse events reported with Immucothel include anaphylaxis, severe hypersensitivity reactions, autoimmune disease flare‑ups, cytokine release syndrome, and rare organ dysfunction such as hepatic or renal impairment. Prompt medical evaluation is required if any of these symptoms occur.

Immucothel should be avoided in individuals with a known hypersensitivity to Immunocyanine or any excipients, patients with active uncontrolled infections, those experiencing an acute autoimmune flare, and persons for whom the risk‑benefit assessment is unfavorable, such as certain pregnant or lactating women without clear clinical justification.